Typewriter Therapeutics

Typewriter Therapeutics announced $56M in Series A financing on September 2, 2026. Typewriter Therapeutics emerged from stealth with a $56 million Series A led by AN Venture Partners and RA Capital Management to develop in vivo CAR T medicines.

Round details

The financing includes backing from AN Venture Partners, RA Capital Management, ANRI, Gemseki, SBI US Gateway Fund. The company did not publish a valuation with the announcement.

• Round: Series A
• Capital announced: $56M

How the company plans to use the capital

Typewriter Therapeutics said the financing will let it build on its proof-of-concept results in humanized mouse models and establish its first in vivo CAR T development candidate. The release also said the company’s first non-human primate studies are planned for late 2026.

Why this matters for GTM teams

The round was co-led by AN Venture Partners and RA Capital Management for a company whose approach uses lipid nanoparticle-delivered RNA to insert a gene into a safe-harbor site in T cells. The company said its first non-human primate studies are planned for late 2026.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Typewriter Therapeutics Series A announcement.